BRAF and melanoma: Single‐agent trametinib was used as a time‐efficient model for development of drug resistance, which also occurs in response to BRAF inhibition or combined BRAFi + MEKi treatment at longer time points.17 We show that inhibiting either CD271 or autophagy using clinically relevant small‐molecule inhibitors effectively targets the stress‐tolerant state to induce death of MEKi‐resistant melanoma subpopulations.